Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
UNLABELLED: Our goal in this study was to elucidate the mechanisms by which methotrexate radiosensitizes HER2-positive human breast cancer cells to the Auger electron emitter (111)In-trastuzumab modified with nuclear-localization sequence peptides ((111)In-NLS-trastuzumab) and to compare these mecha...
Main Authors: | Costantini, D, Villani, D, Vallis, K, Reilly, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
by: Costantini, D, et al.
Published: (2008) -
(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
by: Costantini, D, et al.
Published: (2007) -
111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
by: Cornelissen, B, et al.
Published: (2012) -
111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012) -
111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)